Digital therapeutics software developer for Parkinson's disease gets £2.1m investment | TheBusinessDesk.com
Summary
Strolll, a digital therapeutics software developer for Parkinsons disease, has secured \xa32.1m of investment.The funding will allow the company to reach several key milestones, including gathering outcomes data from ongoing studies and NHS pilots, expanding into the US market, and demonstrating the ability to apply the technology beyond Parkinsons disease to other conditions.Lichfield-based Strolll is a medical technology company that develops digital therapeutics software for commercially available augmented reality glasses, which transforms physiotherapy and rehabilitation for people living with neurological disorders.The patented software uses proprietary methods to alleviate gait and balance motor symptoms experienced by a large number of people with Parkinsons. It allows patients to access rehabilitation exercise at home and maintain their disease at a lower stage for longer. This improves mobility, confidence, and independence which could reduce the long-term cost burden on families and healthcare systems. This funding forms part of a larger \xa32.1m seed investment round led by MEIF fund manager Midven, part of the Future Planet Capital Group, in participation with Martlet Capital, SFC Capital, and multiple angel investors.Jorgen Ellis, CEO at Strolll, said: We are excited to use this funding to expand the capabilities of Strolll and look forward to working with Midven, and our investors and partners to make this a reality. With this investment, we aim to provide an accessible and effective solution for more patients with neurological disorders, ultimately improving their quality of life.Huw Sparkes, junior investment manager at Midven, said: We are thrilled to support Strolll in its mission to transform the lives of people with Parkinsons disease and relieve strains on the NHS through innovative technology.
Funding
Review available funding amount, funding date, investors, and linked company information related to Digital therapeutics software developer for Parkinson's disease gets £2.1m investment | TheBusinessDesk.com in the interactive ISVWorld profile.